Gorlin stojanovic biography of abraham
•
Abstract
CXCR4 and its ligand CXCL12 medla the homing of progenitor cells in the bone marrow and their recruitment to sites of injury, as well as affect processes such as cell fängelse, survival, and angiogenesis. CXCL12 was long thought to be the sole CXCR4 ligand, but more recently the atypical chemokine macrophage migration inhibitory factor (MIF) was identified as an alternative, non-cognate ligand for CXCR4 and shown to mediate chemotaxis and fängelse of CXCR4-expressing T-cells. This has complicated the understanding of CXCR4-mediated signaling and associated biological processes. Compared to CXCL12/CXCR4-induced signaling, only few details are known on MIF/CXCR4-mediated signaling and it remains unclear to which extent MIF and CXCL12 reciprocally influence CXCR4 binding and signaling. Furthermore, the atypical chemokine receptor 3 (ACKR3) (previously CXCR7) has added to the complexity of CXCR4 signaling due to its ability to bind CXCL12 and MIF, and to evoke CXCL12- and MIF-tr
•
Abstract
Uterine leiomyoma should be considered when a female patient reports symptoms of abdominal pressure and abnormal vaginal bleeding. However, the symptoms of a uterine leiomyoma are vast and overlap with other possible diseases that are difficult to distinguish even with imaging studies. This is why it fryst vatten important for physicians and healthcare providers to keep an open mind and have a broad differential diagnosis.
In this case study, we present a 61-year-old postmenopausal female patient who presented to the emergency department with complaints of pelvic and abdominal pain, as well as vomiting and diarrhea. She was admitted for observation. A complete blood count (CBC), comprehensive metabolic panel (CMP), and urinalysis revealed no abnormalities; a pelvic ultrasound and CT scan reported possible adnexal torsion. The patient remained stable and the pain had subsided when she was seen the next morning by her gynecologist (GYN) who discharged her to follow-up in the office.
•
Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside
Pharmacological therapy for hypertrophic cardiomyopathy (HCM) patients, according to the latest guidelines, includes non-selective drugs such as β-blockers, cardiac-selective calcium antagonists, and disopyramide, to be used in symptomatic patients with obstruction of the left ventricular outflow tract for their negative inotropic effects. |
Current drugs are unable to address the pathophysiological mechanisms of left ventricular dysfunction in HCM and are not, therefore, effective in preventing arrhythmias or slowing down disease progression in HCM patients. |
Novel allosteric inhibitors of myosin are being developed and clinically validated, specifically targeting HCM-related patho-mechanisms, i.e., myocardial hypercontractility and altered energetics. |
1 Introduction
Hypertrophic cardiomyopathy (HCM) is the commonest primitive inherited disease of the myocardi